Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Only minor visual/UI adjustments and timestamp updates were observed; the core study details remain unchanged (To avoid being alerted by small changes, set an alert condition by clicking below).
    Difference
    0.5%
    Check dated 2025-11-03T01:19:35.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    40 days ago
    Change Detected
    Summary
    Overall, the page updates to announce a system status notice and a new software version (v3.2.0), removing the previous v3.1.0 reference.
    Difference
    3%
    Check dated 2025-10-05T10:17:36.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.
    Difference
    0.1%
    Check dated 2025-09-28T03:17:41.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Updated Revision from v3.0.1 to v3.0.2; removed the Back to Top link; overall content remains otherwise unchanged.
    Difference
    0.2%
    Check dated 2025-09-13T17:43:03.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T15:25:49.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, while key medical terms and resources related to pembrolizumab and various lung-related diseases have been removed.
    Difference
    4%
    Check dated 2025-08-30T12:00:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.